This breakthrough translated into a phase II trial evaluating recombinant MAGE‐A3 protein combined with immunostimulants in MAGE‐A3‐positive stage IB–II non‐small cell lung cancer (NSCLC) patients postresection. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.